SCHEMBL4098330

SCHEMBL4098330

CCC(C)CCc1ccccc1C=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 4/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TRIM24 O15164 1/20 0.34
TRIM33 Q9UPN9 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA6 Q15825 1/20 0.34
IGF1R P08069 1/20 0.34
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240401 0.84 MEN1 (0.44) MEN1KMT2ALMNATHRBBLM
SCHEMBL5034600 0.83 SLC6A2 (0.35) ALDH1A1SLC6A2SLC6A4SLC6A3CHRNB2
SCHEMBL15611394 0.82 KMT2A (0.43) MEN1KMT2ALMNATHRBBLM
SCHEMBL11687669 0.81 TYR (0.42) MEN1KMT2ALMNATHRBBLM
SCHEMBL28383697 0.80 SLC6A2 (0.40) TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL547665 0.77 LMNA (0.50) MEN1KMT2ALMNATHRBBLM
SCHEMBL11729960 0.77 MEN1 (0.41) MEN1KMT2ALMNATHRBBLM
Fluoride SCHEMBL14237094 0.76 LMNA (0.48) MEN1KMT2ALMNATHRBBLM
SCHEMBL28727160 0.76 MEN1 (0.36) MEN1KMT2ALMNATHRBBLM
SCHEMBL224815 0.75 LMNA (0.57) MEN1KMT2ALMNATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445516-B2 Pharmaceutical composition for promoting angiogenesis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-05-21 US disclosed
US-20090187025-A1 Pharmaceutical composition for promoting angiogenesis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-07-23 US disclosed
EP-1708705-B1 USE OF PIPERIDINE DERIVATIVES FOR PROMOTING ANGIOGENESIS OTSUKA PHARMA CO LTD (JP) 2009-02-18 EP disclosed
EP-1708705-A1 PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-10-11 EP disclosed
WO-2005072734-A1 PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090187025-A1 Pharmaceutical composition for promoting angiogenesis FLT1, FLT4, KDR MEN1 4115/4885KMT2A 3216/4885LMNA 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.